Poolbeg Pharma (LON:POLB) Shares Down 13.6% – Here’s Why

Poolbeg Pharma PLC (LON:POLB) fell 13.6% during mid-day trading on Tuesday . The stock traded as low as GBX 5.96 and last traded at GBX 6.05. 23,044,447 shares were traded during mid-day trading, an increase of 1,199% from the average session volume of 1,774,020 shares. The stock had previously closed at GBX 7.

Analyst Ratings Changes

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Poolbeg Pharma in a report on Monday.

Poolbeg Pharma Stock Performance

The stock has a market cap of £42.66 million, a PE ratio of -6.44 and a beta of 1.81. The business has a 50 day moving average price of GBX 6.40 and a two-hundred day moving average price of GBX 5.09.

Poolbeg Pharma (LON:POLB) last issued its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) EPS for the quarter. As a group, research analysts anticipate that Poolbeg Pharma PLC will post -0.68 earnings per share for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.